Multi-nutrient supplement improves hormone ratio associated with cancer risk

Journal of Translational Medicine

Andrew B Newberg¹  George P Zabrecky¹  Anthony J Bazzan¹ 

[1] Myrna Brind Center of Integrative Medicine, Thomas Jefferson University, 925 Chestnut Street, Suite 120, Philadelphia, PA 19107, USA

关键词: Flavonoid;    Indole;    Proliferative;    Cancer;    Nutrient;    Hormone;   

Others  :  825305
DOI  :  10.1186/1479-5876-11-252

 received in 2013-07-16, accepted in 2013-09-05,  发布年份 2013

【 摘 要 】

Background

Gynecological cancers are among the most common in women and are directly related to a variety of hormonal factors. One potential risk factor associated with developing a gynecological malignancy is the ratio of two hormone metabolites, 2-Hydroxyestrone (2-HE) and 16alpha-Hydroxyestrone (16alpha-HE). A number of botanical constituents such as indoles, flavonoids, and resveratrol have been shown to have a favorable effect on the metabolic pathways that affect this ratio. The present study was designed to evaluate if a multi-nutrient supplement containing targeted botanical constituents would affect the 2-HE/16 alpha-HE ratio in middle-aged women.

Methods

A retrospective analysis was performed on 76 female patients (mean age 54 years) who received 2-HE/16 alpha-HE ratio assessments at two separate time points. The ratio assessment was part of standard care for women who presented with risk indicators associated with a high proliferative state. All patients who completed pre and post assessments were included. Sixty-five of the patients received a multi-nutrient supplement, Lucentia Peak®, during the study period. Eleven patients chose not to take the supplement, but did receive ratio assessments at similar time points as the treatment group, allowing for between group comparisons. Paired t-tests were used to compare the changes in the 2-HE and 16alpha-HE measures as well as their ratio, both within groups and between groups.

Results

The results demonstrated a significant increase in the 2-HE/16alpha-HE ratio in the treated group (pre 0.38 to post 0.57, p<0.0001), and was significantly different (p=0.02) compared to the change in the control group (pre 0.65 to post 0.64). This change appears to be mediated primarily by an increase in the 2-HE level. Individually, 54 patients given Lucentia Peak® had increased ratios while 11 patients had a decrease. In the control group, 3 patients had an increase in their ratio and 8 patients had a decrease.

Conclusions

The results demonstrated that women receiving the Lucentia Peak® multi-nutrient supplement had significant increases in their 2-HE:16alpha-HE ratio, which appears to be mediated primarily by increasing the 2-HE levels. These results suggest further research on phytonutrients that might positively affect estrogen metabolism is warranted.

【 授权许可】

   
2013 Bazzan et al.; licensee BioMed Central Ltd.

【 参考文献 】

• [1]Cauley JA, Zmuda JM, Danielson ME, Ljung BM, Bauer DC, Cummings SR, Kuller LH: Estrogen metabolites and the risk of breast cancer in older women. Epidemiology 2003, 14:740-744.
• [2]Ursin G, London S, Stanczyk FZ, Gentzschein E, Paganini-Hill A, Ross RK, Pike MC: Urinary 2-hydroxyestrone/16alpha-hydroxyestrone ratio and risk of breast cancer in postmenopausal women. J Natl Cancer Inst 1999, 91:1067-1072.
• [3]Obi N, Vrieling A, Heinz J, Chang-Claude J: Estrogen metabolite ratio: Is the 2-hydroxyestrone to 16α-hydroxyestrone ratio predictive for breast cancer? Int J Womens Health 2011, 3:37-51.
• [4]Fuhrman BJ, Schairer C, Gail MH, Boyd-Morin J, Xu X, Sue LY, Buys SS, Isaacs C, Keefer LK, Veenstra TD, Berg CD, Hoover RN, Ziegler RG: Estrogen metabolism and risk of breast cancer in postmenopausal women. J Natl Cancer Inst 2012, 104:326-339.
• [5]Muti P, Bradlow HL, Micheli A, Krogh V, Freudenheim JL, Schünemann HJ, Stanulla M, Yang J, Sepkovic DW, Trevisan M, Berrino F: Estrogen metabolism and risk of breast cancer: a prospective study of the 2:16alpha-hydroxyestrone ratio in premenopausal and postmenopausal women. Epidemiology 2000, 11:635-640.
• [6]Firestone GL, Sundar SN: Minireview: modulation of hormone receptor signaling by dietary anticancer indoles. Mol Endocrinol 2009, 23:1940-1947.
• [7]Wong GY, Bradlow L, Sepkovic D, Mehl S, Mailman J, Osborne MP: Dose-ranging study of indole-3-carbinol for breast cancer prevention. J Cell Biochem Suppl 1997, 28–29:111-116.
• [8]Wormke M, Stoner M, Saville B, Walker K, Abdelrahim M, Burghardt R, Safe S: The aryl hydrocarbon receptor mediates degradation of estrogen receptor through activation of proteasomes. Mol Cell Biol 2003, 23:1843-1855.
• [9]Okino ST, Pookot D, Basak S, Dahiya R: Toxic and chemopreventive ligands preferentially activate distinct aryl hydrocarbon receptor pathways: implications for cancer prevention. Cancer Prev Res 2009, 2:251-256.
• [10]Manthey JA, Guthrie N: Antiproliferative activities of citrus flavonoids against six human cancer cell lines. J Agric Food Chem 2002, 50:5837-5843.
• [11]Mercader AG, Pomilio AB: Naturally-occurring dimers of flavonoids as anticarcinogens. Anticancer Agents Med Chem 2013. [Epub ahead of print]
• [12]Wani BA, Ramamoorthy D, Rather MA, Arumugam N, Qazi AK, Majeed R, Hamid A, Ganie SA, Ganai BA, Anand R, Gupta AP: Induction of apoptosis in human pancreatic MiaPaCa-2 cells through the loss of mitochondrial membrane potential (ΔΨm) by Gentiana kurroo root extract and LC-ESI-MS analysis of its principal constituents. Phytomedicine 2013, 20:723-733.
• [13]Nijveldt RJ, van Nood E, van Hoorn DE, Boelens PG, van Norren K, van Leeuwen PA: Flavonoids: a review of probable mechanisms of action and potential applications. Am J Clin Nutr 2001, 74:418-425.
• [14]Stefani ED, Boffetta P, Deneo-Pellegrini H, Mendilaharsu M, Carzoglio JC, Ronco A, Olivera L: Dietary antioxidants and lung cancer risk: a case–control study in Uruguay. Nutr Cancer 1999, 34:100-110.
• [15]Fotsis T, Pepper MS, Aktas E, Breit S, Rasku S, Adlercreutz H, Wähälä K, Montesano R, Schweigerer L: Flavonoids, dietary-derived inhibitors of cell proliferation and in vitro angiogenesis. Cancer Res 1997, 57:2916-2921.
• [16]Reed GA, Peterson KS, Smith HJ, Gray JC, Sullivan DK, Mayo MS, Crowell JA, Hurwitz A: A phase I study of indole-3-carbinol in women: tolerability and effects. Cancer Epidemiol Biomarkers Prev 2005, 14:1953-1960.
• [17]Eliassen AH, Spiegelman D, Xu X, Keefer LK, Veenstra TD, Barbieri RL, Willett WC, Hankinson SE, Ziegler RG: Urinary estrogens and estrogen metabolites and subsequent risk of breast cancer among premenopausal women. Cancer Res 2012, 72:696-706.
• [18]So FV, Guthrie N, Chambers AF, Carroll KK: Inhibition of proliferation of estrogen receptor-positive MCF-7 human breast cancer cells by flavonoids in the presence and absence of excess estrogen. Cancer Lett 1997, 112:127-133.
• [19]Guo Y, Zhang X, Meng J, Wang ZY: An anticancer agent icaritin induces sustained activation of the extracellular signal-regulated kinase (ERK) pathway and inhibits growth of breast cancer cells. Eur J Pharmacol 2011, 658:114-122.
• [20]Yap SP, Shen P, Li J, Lee LS, Yong EL: Molecular and pharmacodynamic properties of estrogenic extracts from the traditional Chinese medicinal herb, Epimedium. J Ethnopharmacol 2007, 113:218-224.
• [21]Kolodziejczyk-Czepas J: Trifolium species-derived substances and extracts–biological activity and prospects for medicinal applications. J Ethnopharmacol 2012, 143:14-23.
• [22]Gopalan A, Reuben SC, Ahmed S, Darvesh AS, Hohmann J, Bishayee A: The health benefits of blackcurrants. Food Funct 2012, 3:795-809.
• [23]Hong C, Kim HA, Firestone GL, Bjeldanes LF: 3,3'-Diindolylmethane (DIM) induces a G(1) cell cycle arrest in human breast cancer cells that is accompanied by Sp1-mediated activation of p21(WAF1/CIP1) expression. Carcinogenesis 2002, 23:1297-1305.
• [24]Dalessandri KM, Firestone GL, Fitch MD, Bradlow HL, Bjeldanes LF: Pilot study: effect of 3,3'-diindolylmethane supplements on urinary hormone metabolites in postmenopausal women with a history of early-stage breast cancer. Nutr Cancer 2004, 50:161-167.
• [25]Zahid M, Saeed M, Beseler C, Rogan EG, Cavalieri EL: Resveratrol and N-acetylcysteine block the cancer-initiating step in MCF-10F cells. Free Radic Biol Med 2011, 50:78-85.
• [26]McLay JS, Stewart D, George J, Rore C, Heys SD: Complementary and alternative medicines use by Scottish women with breast cancer. What, why and the potential for drug interactions? Eur J Clin Pharmacol 2012, 68:811-819.